Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
| ▸ | JAK2 | O60674 | 13/20 | 0.35 |
| ▸ | JAK1 | P23458 | 13/20 | 0.35 |
| ▸ | TYK2 | P29597 | 13/20 | 0.35 |
| ▸ | JAK3 | P52333 | 13/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27128360 | 1.00 | ACHE (0.41) | ACHEJAK2JAK1TYK2JAK3 | |
| SCHEMBL25068422 | 0.87 | ACHE (0.38) | ACHEJAK2JAK1TYK2JAK3 | |
| SCHEMBL27031917 | 0.85 | JAK2 (0.39) | ACHEJAK2JAK1TYK2JAK3 | |
| SCHEMBL27032066 | 0.85 | JAK2 (0.39) | ACHEJAK2JAK1TYK2JAK3 | |
| SCHEMBL20520119 | 0.85 | JAK2 (0.39) | ACHEJAK2JAK1TYK2JAK3 | |
| SCHEMBL29139484 | 0.79 | ACHE (0.50) | ACHEJAK2JAK1TYK2JAK3 | |
| SCHEMBL27120344 | 0.78 | ACHE (0.35) | ACHE | |
| SCHEMBL671486 | 0.74 | — | — | |
| SCHEMBL25244245 | 0.72 | ACHE (0.32) | ACHE | |
| SCHEMBL13738737 | 0.72 | JAK2 (0.36) | ACHEJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| EP-4308570-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425661-A | Macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2024-01-19 | — | — | CN | disclosed |
| WO-2022194976-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PARK7, PINK1 | ACHE 3482/4885JAK2 685/4885JAK1 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.